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Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
Opsonins are soluble, extracellular proteins, released by activated immune cells, and
when bound to a target cell, can induce phagocytes to phagocytose the target cell.
There are three known classes of opsonin: antibodies, complement factors and secreted
pattern recognition receptors, but these have limited access to the brain. We identify
here two novel opsonins of bacteria, calreticulin, and galectin-3 (both lectins that can
bind lipopolysaccharide), which were released by microglia (brain-resident macrophages)
when activated by bacterial lipopolysaccharide. Calreticulin and galectin-3 both bound to
Escherichia coli, and when bound increased phagocytosis of these bacteria by microglia.
Furthermore, lipopolysaccharide-induced microglial phagocytosis of E. coli bacteria was
partially inhibited by: sugars, an anti-calreticulin antibody, a blocker of the calreticulin
phagocytic receptor LRP1, a blocker of the galectin-3 phagocytic receptor MerTK, or
simply removing factors released from the microglia, indicating this phagocytosis is
dependent on extracellular calreticulin and galectin-3. Thus, calreticulin and galectin-3
are opsonins, released by activated microglia to promote clearance of bacteria. This
innate immune response of microglia may help clear bacterial infections of the brain.
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INTRODUCTION
Bacterial infections of the brain are serious, often causing death or irreversible brain damage
(1). They are relatively rare in developed countries, but still relatively common in some
developing countries (2). Infections include bacterial meningitis, bacterial encephalitis, bacterial
meningoencephalitis, and brain abscess (1). Bacterial infection of the brain appears to increase in
Alzheimer’s disease, and might contribute to this disease (3). Brain infections are serious partly
because antibodies and leucocytes have limited access to the brain, so that microglia (brain-resident
macrophages) act as the primary innate immune response to bacterial infection of the brain. One
of the main ways that microglia combat bacterial infection is by phagocytosing the bacteria (4).
Phagocytosis is the cellular engulfment and digestion by cells of large extracellular particles,
including bacteria. Phagocytes are cells specialized in phagocytosis, and their phagocytosis of other
cells (the target cell) normally requires: an “eat-me” signal on the target cell, a phagocytic receptor
on the phagocyte, and an opsonin to link the receptor and eat-me signal (5). An eat-me signal is a
molecule normally found inside the target cell, but when exposed on the surface of the target cell
promotes a phagocyte to phagocytose that cell. A phagocytic receptor is a receptor on a phagocyte
that, when activated by an eat-me signal or opsonin on the target cell, induces engulfment of the
target cell by the phagocyte. Opsonins are normally soluble, extracellular proteins that when bound
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to the surface of cells promote phagocytosis of those cells.
Classical opsonins include IgG antibodies and complement
components, but also pentraxins, collectins, and ficolins.
Here, we identify two novel opsonins of bacteria, galectin-3,
and calreticulin.
Galectin-3 (gal-3), also known as Mac-2 or LGALS3, is a
protein expressed and released by macrophages and microglia
(6–9). It is a galactose-binding lectin (galectin) that preferentially
binds to N-acetyl-lactosamine (a disaccharide of galactose
and N-acetyl-glucosamine) in glycoproteins or gangliosides
(7, 10). Galectin-3 is normally monomeric, but when the C-
terminal carbohydrate recognition domain (CRD) binds N-
acetyl-lactosamine, the N-terminal oligomerizes, so that galectin-
3 can cross link glycoproteins or gangliosides (7, 10). By binding
to sugars on target cells and then crosslinking to phagocytic
receptors on phagocytes, galectin-3 can potentially act as an eat-
me signal or opsonin (9, 11). However, it is not known whether
galectin-3 can opsonise bacteria.
Calreticulin is a protein normally found in the endoplasmic
reticulum where it acts as a chaperone, binding to terminal
glucose residues on developing glycoprotein oligosaccharides
(12). However, in conditions of apoptosis or endoplasmic
reticulum stress, calreticulin can translocate to the cell surface,
and some cells such as neutrophils constitutively express
calreticulin on the cell surface (13, 14). Surface-exposed
calreticulin has been demonstrated to act as an eat-me signal
to macrophages (13, 15–17). Surface-exposed calreticulin is
recognized by the phagocytic receptor LRP1 on phagocytes (13,
18), although calreticulin is also found associated with LRP1 on
the phagocyte membrane where it acts as a co-receptor for LRP1
ligands such as C1q and alpha-2-macroglobulin (19, 20). Note,
however, that calreticulin is a soluble protein, and therefore has
the potential to be released into the extracellular space (21), where
in principle it might act as an opsonin.
In this paper, we show that calreticulin and galectin-3 can be
released by a phagocyte, microglia, when activated, and can then
bind to and opsonise bacteria for phagocytosis by the microglia.
MATERIALS AND METHODS
All experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act (1986) and approved by the
Cambridge University Local Research Ethics Committee.
Cell Culture and Treatments
Primary microglia were prepared from mixed glial cultures
from the cortices of postnatal day 4–6 mice or rats as
described (22, 23). After removal of meninges and mechanical
dissociation, cortices were matured in vitro for at least 6
days using Dulbecco’s modified Eagle’s medium (DMEM)
Abbreviations: LRP1, low-density lipoprotein receptor-related protein 1;
sLRP1, soluble low-density lipoprotein receptor-related protein 1; LPS,
lipopolysaccharide; Gal-3, galectin-3; MHCII, major histocompatibility
complex II; MerTK, Mer tyrosine kinase; TAMRA, 5-(and-6)-carboxytetra-
methylrhodamine; TREM2, triggering receptor expressed on myeloid cells 2;
TLR4, toll-like receptor 4; mLRPAP (or RAP), mouse LRP-associated protein; CSF,
cerebrospinal fluid.
(ThermoFisher, California, USA) supplemented with 10%
performance-plus fetal bovine serum (FBS) (ThermoFisher,
California, USA), before removing microglia by shaking-
off and plating in culture medium (a 1:2 ratio of old
“conditioned” medium: fresh medium) on well-plates pre-
coated with poly-L-lysine (Sigma, Missouri, USA). BV2 mouse
microglial cells were maintained in DMEM supplemented with
10% FBS. All tissue culture medium was supplemented with
100 U/ml penicillin/streptomycin (ThermoFisher, California,
USA). DH5α Escherichia coli for phagocytosis experiments
were grown shaking in LB media at 37◦C. The following
reagents were used: lipopolysaccharide (LPS) from Salmonella
(serotype: typhimurium) or E. coli, 5-(and-6)-carboxytetra-
methylrhodamine (TAMRA), Cytochalasin D, D-glucose and
D-lactose were from Sigma-Aldrich. Recombinant human
Calreticulin protein (Abcam, Cambridge, UK), pHRODO Red
succinimidyl-ester and sucrose (ThermoFisher, California, USA),
recombinant human LRPAP protein (RAP) (R&D systems,
Minneapolis, MN, USA), UNC569 (Calbiochem, MA, USA),
UNC2881 (Selleckchem, TX, USA), anti-Calreticulin polyclonal
antibody (Enzo Life Sciences, NY, USA), rabbit polyclonal
IgG antibody (Southern Biotech, AL, USA). Human galectin-
3 was provided as a kind gift from Tomas Deierborg (Lund
university). Antibodies were Fc-blocked using an Affinipure
Fab fragment goat anti-rabbit IgG (Jackson ImmunoResearch,
Cambridge, UK).
RNA Isolation and RT-qPCR
RNA was isolated from microglial BV2 cells using Monarch
Total RNA Miniprep Kit (New England Biolabs, Massachusetts,
USA), and cDNA was generated from 1 µg RNA and random
hexamer primers using the SuperScript II Reverse Transcriptase
Kit (ThermoFisher, California, USA). qT-PCR was run with
the Platinum SYBR Green qPCR SuperMix (ThermoFisher,
California, USA) using a Rotor-Gene Q cycler (Qiagen, Hilden,
Germany). Primers against mouse CALR, LGALS3, and IL6
were used, with ACTB (β-actin) as the internal control
(Sigma, Missouri, USA). Relative mRNA levels of target genes
were analyzed by comparing fold-changes in the delta-delta
threshold cycle, after normalizing against the internal control for
each condition.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Primary microglia from mice—chosen for species-specificity
of available antibodies—were plated at densities of 10,000
cells/100 µl/well (96 well-plate format) in culture medium.
Cells were treated for 24 h, and cell media was extracted
and subjected to a calreticulin ELISA (Abbexa, Cambridge,
UK) or galectin-3 ELISA (R&D Systems, Minneapolis,
USA) as per manufacturer’s instructions. Absorbances
at 450 nm were measured using a FLUOstar Optima
plate reader (BMG Labtech, Ortenberg, Germany) and
represented as protein concentration calculated against a
standard curve.
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TAMRA-Conjugated Protein Binding
Assays
Calreticulin and galectin-3 were incubated with amine-reactive
5-(and-6)-carboxytetra-methylrhodamine (TAMRA, 50µM) for
20min at 37◦C before diluting in 15ml PBS. Proteins were spun
down using an Amicon Ultracentrifuge filter (Millipore, Merck,
New Jersey, USA) with a molecular weight cut-off 10,000 Daltons
to remove unbound TAMRA. E. coli were then resuspended in
either the protein-positive fraction, or the protein-free eluant as
a control.
Microglial Phagocytosis Assays
Primary microglia from rat (chosen due to greater cellular yield
compared to mice) were plated at densities of 50,000 cells/200
µl/well (96 well-plate format) in culture medium. For LPS
experiments, cells were treated with vehicle or 100 ng/ml LPS
within 60min of seeding. LPS from S. enterica was used in all
cases except for Figure 5C, which was LPS from E. coli. E. coli
were grown shaking overnight in LB media (37◦C). Bacteria
were heat-inactivated at 65◦C for 15min before centrifuging
at 6,000× g for 5min and resuspending in PBS. Bacteria were
stained with amine-reactive pHrodo Red succinimidyl-ester at
10µM for 20min (37◦C) before washing several times in PBS
via centrifugation and resuspension to remove unconjugated
pHrodo. Bacteria were resuspended in PBS, and either incubated
for 90min with opsonins (followed by several wash steps) or
added directly to cells, and maintained in an incubator (37◦C, 5%
CO2-infused) for the 1-h phagocytosis assay. Primary microglia
were detached via trypsinization and resuspended in 60 µl PBS.
Samples were maintained in darkness on ice and taken directly
for FACS analysis using an Accuri C6 Flow Cytometer (BD
services, San Jose, CA, USA). Sucrose (50mM), lactose (50mM),
UNC569 (5µM), UNC2881 (200 nM), mLRPAP (250 nM or
500 nM) or cytochalasin D (10µM) were added to cells 60min
prior to bacteria; anti-calreticulin or IgG serotype control
(2µg/ml) were added to cells 3 h prior to bacteria.
Cell Viability Assay
Cell viability was measured using the DNA-staining dye
propidium iodide (Sigma, Missouri, USA). Cells were stained
with propidium iodide (1.5µM) for 20min and staining was
quantified via flow cytometry using anAccuri C6 FlowCytometer
(BD, New Jersey, USA).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
version 8. All results contained herein represent mean values
averaged from at least three independent experiments. Standard
error of the mean (SEM) is represented as error bars in all cases.
Figures comparing just two conditions were analyzed using a
Student’s t-test; all other data was analyzed using one- or two-way
ANOVA and post-hoc Tukey’s multiple comparison test.
RESULTS
Calreticulin is known to function as an eat-me signal or as
a phagocytic co-receptor, but it is unclear whether it can act
as an opsonin, which would require that it was released from
cells, normally inflammatory-activated immune cells. Therefore,
we tested whether calreticulin is released extracellularly from
microglial cells, and whether any such release was enhanced
by inflammatory activation of the microglia. Supernatants from
primary mouse microglia ± LPS were isolated, and calreticulin
was measured by ELISA (Figure 1A). We found that media
conditioned with vehicle-treated microglia contained small, but
statistically insignificant levels of calreticulin (1.29± 0.93 ng/ml),
when compared to media which had not seen cells (p = 0.695).
However, 24 h of LPS treatment triggered a dramatic increase in
calreticulin released from these cells (7.28 ± 1.87 ng/ml), which
was significantly higher than that from non-activated cells (p =
0.017), or when compared to cell-free media (p = 0.004). To
rule out the possibility of necrotic leakage of calreticulin from
cells after treatment, cells were stained with propidium iodide
and quantified—no significant increases in necrosis after LPS
treatment was observed (data not shown).
Galectin-3 is known to be released from blood-marrow
macrophages and BV2 cells in response to LPS stimulation (8, 9,
24). So, we tested whether primary mouse microglia also released
galectin-3 into the culture medium using an ELISA. We found
that unstimulated microglia released galectin-3 into the medium
(1.09 ± 0.185 ng/ml, p < 0.01), and this release was increased by
LPS (1.73± 0.13 ng/ml) (Figure 1B; p= 0.02).
To test whether LPS affected calreticulin expression, RNA was
isolated from mouse microglial BV2 cells treated ± LPS for 24 h,
and calreticulin RNA was measured by qPCR. LPS was found
to increase calreticulin mRNA by 35% (± 4) at this time-point
(Figure S1A). Similarly, LPS increased galectin-3 mRNA by 19%
(± 5) (Figure S1B), suggesting that LPS triggers upregulation as
well as release of calreticulin and galectin-3 in microglia.
To assay microglial phagocytosis of bacteria, we labeled
E. coli with amine-reactive pHrodo Red succinimidyl ester
(10µM), which covalently binds the bacteria, but only fluoresces
when the bacteria are delivered into the acidic lysosome
during phagocytosis. Labeled bacteria were incubated with
microglial BV2 cells (used initially to optimize the assay)
and phagocytosis was quantified by flow cytometry—there was
a linear increase in fluorescence over the first 120min of
incubation (Figure S2). Having optimized the assay in BV2
cells, we then switched to using primary rat microglia, because
they are more physiologically relevant than BV2 cells, and
are obtainable in higher yields than primary mouse microglia.
Labeled bacteria were incubated with primary rat microglia for
60min; phagocytosis was confirmed by microscopy (Figure 2A)
and quantified by flow cytometry (Figure 2B). Cytochalasin D, an
inhibitor of phagocytosis, completely abolished the fluorescence
increase when applied at 10µM (p < 0.0001; p = 0.528 vs.
the control without bacteria), confirming that the fluorescence
increase was due to phagocytosis.
Calreticulin and galectin-3 are sugar-binding proteins
known to have binding affinity for bacterial LPS (25, 26).
LPS (lipopolysaccharide) contains many sugar residues and
constitutes much of the surface of gram-negative bacteria. So
calreticulin and galectin-3 could potentially bind gram-negative
bacteria such as E. coli. To test whether calreticulin or galectin-3
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FIGURE 1 | Microglial calreticulin and galectin-3 are released extracellularly following LPS stimulation. (A,B) Primary microglia from mice were treated with vehicle or
LPS (100 ng/ml) for 24 h. Cell-conditioned supernatant was tested for calreticulin protein (A) or galectin-3 (B) presence via ELISA and compared with the “no cells”
control. Statistical comparisons were made via one-way ANOVA. Values are means ± SEM of at least three independent experiments. NS p ≥ 0.05, *p < 0.05, **p <
0.01, ****p < 0.0001 vs. controls, except where indicated by bars over relevant columns.
can bind E. coli, we labeled recombinant calreticulin and
galectin-3 with the amine-reactive fluorophore TAMRA (5-(and
6-)carboxytetramethylrhodamine) (50µM) and incubated
this with heat-inactivated E. coli for 1 h to measure protein
binding to the bacteria via flow cytometry. Bacterial fluorescence
readings were significantly increased in the presence of TAMRA-
calreticulin protein compared to the protein-free control
(Figure 3A). Similarly, TAMRA-labeled galectin-3 bound to E.
coli (Figure 3A), indicating that both calreticulin and galectin-3
can bind to bacteria.
We next tested whether calreticulin can opsonize bacteria
for microglial phagocytosis. pHrodo-conjugated E. coli were
incubated with 500 nM calreticulin for 90min (followed by
several washing steps to remove unbound protein), and this
increased their phagocytic removal by microglia by 118%
(±29) compared to E. coli not incubated with calreticulin
(Figure 3B). This opsonization was abolished in the presence of
sucrose (Figure 3C), consistent with a role for the carbohydrate-
recognition domain of calreticulin in bacterial binding. Sucrose
was not able to significantly inhibit microglial phagocytosis
of bacteria in the absence of exogenous calreticulin. This is
consistent with the lack of a significant release of calreticulin by
non-activated microglia demonstrated previously (Figure 1A),
and suggests that calreticulin can promote, but is not required,
for bacterial clearance by unstimulated microglia.
We have previously shown that calreticulin can opsonise
PC12 cells via the microglial phagocytic receptor LRP1, which is
inhibited by the LRP1-specific ligand RAP (27). So, to investigate
whether exogenous calreticulin mediates microglial phagocytosis
of bacteria via LRP1, we tested whether RAP affected the
calreticulin-induced microglial phagocytosis of bacteria. We
found that treating the cells with RAP inhibited this phagocytosis
to control levels (Figure 3D). Together, these data suggest that
calreticulin opsonized bacteria for microglial phagocytosis via
(i) it’s carbohydrate-recognition domain and (ii) the microglial
LRP1 receptor.
We next tested whether galectin-3 can also opsonize
bacteria for microglial phagocytosis. E. coli were incubated
with 20 nM galectin-3 (followed by several washes)
and added to primary rat microglia for 90min before
measuring phagocytosis. Pre-incubation of the bacteria
with galectin-3 enhanced their phagocytosis by microglia
by 73% (±24) (Figure 4A). Thus, added galectin-3 can also
opsonise bacteria. Galectin-3 binds lactose, and lactose can
inhibit the ability of galectin-3 to opsonise mammalian
cells (9). So, we tested the effect of lactose on our cells.
Treating with lactose inhibited microglial phagocytosis of
bacteria in the presence or absence of exogenous galectin-
3 (Figure 4B), suggesting that sugars are involved in
this phagocytosis.
It is known that galectin-3 can opsonise mammalian cells
by bridging between sugars on the target cells and the
phagocytic receptor MerTK to promote microglial phagocytosis
of certain cell types (9, 11). To test whether the galectin-3
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FIGURE 2 | Primary rat microglia rapidly phagocytose E. coli bacteria in vitro. (A) Primary rat microglia phagocytose pHrodo-conjugated E. coli over 60min in culture,
which was prevented by cytochalasin D (10µM). (B) Microglial phagocytosis of pHrodo-conjugated E. coli was quantified as mean red fluorescence via flow
cytometry; there is a significant increase in microglial fluorescence after 60-min with E. coli which is abolished by cytochalasin D, when compared to the “-bacteria”
control. Values are means ± SEM of at least three independent experiments. Statistical comparisons were made via one-way ANOVA. NS p ≥ 0.05, ***p < 0.001,
****p < 0.0001 vs. controls, except where indicated by bars over relevant columns.
opsonization of bacteria activates phagocytosis via microglial
MerTK, cells were briefly treated (or not) with the MerTK-
specific inhibitor UNC569 and bacterial phagocytosis was
measured as before. In the presence and absence of exogenous
galectin-3, UNC569 strongly inhibited microglial phagocytosis
of bacteria (Figure 4C), without affecting microglial viability
(Figure 4D). This is consistent with MerTK being the main
phagocytic receptor for microglial phagocytosis of the bacteria
in the presence or absence of exogenous galectin-3; and suggests
that galectin-3 opsonizes bacteria for microglial phagocytosis
via MerTK.
LPS, along with other agonists for microglial TLR4, is
known to promote increased phagocytosis of bacteria and
other pathogenic species by microglia (28–30). Given LPS
induces calreticulin and galectin-3 release from microglia, and
that these proteins are capable of opsonizing bacteria for
phagocytic removal in culture, we hypothesized that these
opsonins may mediate the LPS-induction increase in microglial
phagocytosis of bacteria. To investigate this, microglia were
stimulated with LPS for 24 h before co-incubation with E.
coli for an hour, and phagocytosis was measured as before
(Figure 5A). LPS did indeed increase microglial phagocytosis
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FIGURE 3 | Calreticulin opsonizes E. coli for microglial phagocytosis. (A) TAMRA-conjugated calreticulin (500 nM) and galectin-3 (20 nM) bind E. coli after 90min
co-incubation, measured in terms of relative fluorescence unit increase vs. the vehicle (protein-free) control. (B) Recombinant calreticulin (500 nM) opsonizes E. coli for
microglial phagocytosis when pre-incubated for 90min (and subsequently washed to remove unbound protein). (C,D) Opsonization of E. coli for microglial
phagocytosis by recombinant calreticulin is inhibitable by 50mM sucrose when compared to “–calreticulin – sucrose” control (C) or 500 nM RAP (a LRP1 inhibitor)
when compared to “–calreticulin – RAP” control (D). Values are means ± SEM of at least three independent experiments. Statistical comparisons were made via one-
or two-way ANOVA except for (B), which was by pair-wise student’s t-test. NS p ≥ 0.05, **p < 0.01, ***p < 0.001 vs. controls, except where indicated by bars over
relevant columns.
of bacteria by 56% on average (±22%). To test whether this
LPS-induced phagocytosis depends on extracellular components
(including opsonins), a media swap was performed (removing
any factors released by the microglia) immediately prior
to bacterial addition and the effect on phagocytosis was
determined (Figure 5B). Phagocytosis by unstimulated microglia
was unaffected by the media swap, but phagocytosis by LPS-
stimulated microglia was significantly inhibited (p = 0.015)
to levels not significantly different from the control (p =
0.944). This indicates that factors released by the microglia in
response to LPS are responsible for the increased phagocytosis,
consistent with the increased phagocytosis being due to a released
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FIGURE 4 | Galectin-3 opsonizes E. coli for microglial phagocytosis. (A) Recombinant galectin-3 (20 nM) opsonizes E. coli for microglial phagocytosis when
pre-incubated for 90min (and subsequently washed to remove unbound protein). (B,C) Opsonization of E. coli for microglial phagocytosis by recombinant galectin-3
is inhibitable by 50mM lactose when compared to “–gal-3 – lactose” control (B), or 5µM UNC569 (a MerTK inhibitor) when compared to “–gal-3 – UNC569” control
(C) (note that a statistically significant difference between “–gal-3 – lactose” and “–gal-3 + lactose” was observed). (D) UNC569 (5µM for 2 h) does not promote
necrotic death of primary rat microglial cells in culture compared to the “vehicle” control, determined by propidium-iodide staining and quantified via flow cytometry.
Manganese chloride (MnCl2, 1mM) was used as a positive control for necrotic death. Values are means ± SEM of at least three independent experiments. Statistical
comparisons were made via one- or two-way ANOVA except for (A), which was by pair-wise student’s t-test. NS p ≥ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 vs.
controls, except where indicated by bars over relevant columns.
opsonin, rather than an increased phagocytic capacity of the
microglia themselves.
To test more directly whether extracellular calreticulin
mediates LPS-induced microglial phagocytosis of bacteria,
microglia were treated for 3 h with a function-blocking anti-
calreticulin antibody prior to co-incubation with bacteria, and
the induction of phagocytosis by LPS was measured. Anti-
calreticulin was able to inhibit the LPS-induced increase in
phagocytosis when compared to a serotype control IgG (p =
0.029, Figure 5C). Anti-calreticulin had no effect on phagocytosis
in the absence of LPS (Figure 5C), consistent with calreticulin
being absent in this condition (Figure 1A). Together, this
indicates that the LPS-induced phagocytosis is at least partly due
to the LPS-induced release of calreticulin.
We further tested whether lactose or sucrose could inhibit this
LPS induction of phagocytosis. Phagocytosis in the presence of
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FIGURE 5 | LPS-induced phagocytosis of bacteria by primary microglia is mediated by extracellular calreticulin. (A) Primary rat microglia stimulated by LPS
(100 ng/ml) for 24 h significantly increase their phagocytosis of E. coli compared to the “-LPS” control. (B) LPS-induced phagocytosis is inhibited by applying a media
swap immediately prior to bacterial addition, compared to the “–LPS – media swap” control. (C) LPS-induced phagocytosis is inhibited in the presence of a
function-blocking anti-calreticulin antibody, compared to the “–LPS + IgG” control. Values are means ± SEM of at least three independent experiments. Statistical
comparisons were made via student’s t-test (A) or via two-way ANOVA (B,C). NS p ≥ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 vs. controls, except where indicated
by bars over relevant columns.
LPS was significantly inhibited by lactose (p= 0.0012) or sucrose
(p < 0.0001) to levels not significantly different from the control
in the absence of LPS (Figure 6A).
Given that the LRP1 inhibitor RAP was able to inhibit
calreticulin-induced opsonization of the E. coli, we tested
whether RAP could also inhibit the LPS-induced microglial
phagocytosis of the bacteria. We found that RAP significantly
inhibited the LPS-induced phagocytosis (p = 0.021, Figure 6B).
The MerTK-specific antagonist UNC2881 also inhibited LPS-
inducedmicroglial phagocytosis of bacteria (p= 0.02; p= 0.26 vs.
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FIGURE 6 | LPS-induced phagocytosis of bacteria by primary microglia is inhibited by sugars, or by blocking microglial LRP1 or MerTK. Primary rat microglia
stimulated by LPS (100 ng/ml) for 24 h increased their phagocytosis of E. coli compared to “–LPS” control, inhibitable by (A) 50mM lactose or sucrose, (B) RAP
(250 nM), or (C) UNC2881 (200 nM). Note that a statistically significant difference between “–LPS + lactose” and “+LPS + lactose” was observed in (A). Values are
means ± SEM of at least three independent experiments. Statistical comparisons were made via two-way ANOVA. NS p ≥ 0.05, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 vs. controls, except where indicated by bars over relevant columns.
the “–LPS –UNC2881” control) (Figure 6C), indicating a role for
galectin-3 and MerTK. Taken together, these data demonstrate
that both calreticulin and galectin-3 are required for the LPS-
induction of bacterial phagocytosis, and this is mediated via their
carbohydrate-binding domains and the microglial phagocytic
receptors LRP1 and MerTK.
DISCUSSION
As calreticulin has been described alternatively as: (i) an eat-
me signal and (ii) a phagocytic receptor, and in this paper we
find it acts as (iii) an opsonin, it is important to distinguish
between use of these terms. An eat-me signal is a signal
normally inside the cell that when exposed on the surface
of a cell induces phagocytes to phagocytose that cell. The
classical eat-me signal is phosphatidylserine, normally found
on the inner leaflet of the plasma membrane but exposed
on the outer leaflet during apoptosis in order to promote
phagocytosis of the apoptotic cell. Calreticulin is normally
found within the cell but can translocate to the surface of
apoptotic cells to promote phagocytosis of these cells, and
therefore can act as an eat-me signal (13). Calreticulin can
also translocate to the surface of phagocytes, where it can act
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as a phagocytic receptor together with LRP1 (31). However,
in contrast to typical eat-me signals and phagocytic receptors,
calreticulin is a soluble protein, which can potentially dissociate
from the surface of cells into the extracellular space, where
it has the potential to act as an opsonin. Galectin-3 has a
similarly ambiguous status: it has been described as an eat-
me signal (11), but it is also found in the extracellular space
and when binding to the surface of target cells can potentially
act as an opsonin (11), and in principle when galectin-3
binds to a phagocytic receptor on a phagocyte it could act
as co-receptor.
We found that microglia activated with LPS released
calreticulin into the extracellular space. These are two important
characteristics of an opsonin, that it can exist as a soluble,
extracellular protein, and that it can be released according to
need, in this case in response to LPS, a marker of the presence
of gram-negative bacteria. Additionally, recombinant calreticulin
bound to the surface of the gram-negative bacteria E. coli,
and when bound promoted phagocytosis of these bacteria by
microglia. Furthermore, LPS-induced phagocytosis of bacteria
was at least in part mediated by the released calreticulin. Thus,
calreticulin fits the core definition of an opsonin: it binds cells
and promotes the phagocytosis of those cells when bound.
So, is calreticulin a eat-me signal, an opsonin or a phagocytic
receptor? It meets the criteria for all three, although it would be
better described as a co-receptor (with LRP1) than a receptor,
as it has no transmembrane signaling capacity. When released
from a target cell onto the target cell surface, it acts as an eat-me
signal. When released from a phagocyte and binding to a target
cell, it acts as an opsonin. When released from a phagocyte onto
the surface of a phagocyte and binding to LRP, it can act as a
co-receptor (31).
What about galectin-3? We found evidence that: galectin-
3 was released from LPS-activated microglia, added galectin-
3 could bind E. coli bacteria and stimulate their phagocytosis
by microglia, and LPS-induced phagocytosis of bacteria was
partly mediated by released galectin-3, indicating that galectin-
3 is an opsonin. Galectin-3 has been described as an eat-me
signal (11), however, although these authors found that galectin-
3 could induce and mediate phagocytosis, they did not find
that galectin-3 was released from the target cells onto their
surface. Thus, they did not provide evidence that galectin-3
can act as an eat-me signal, rather than as an opsonin. We
(9) reported that galectin-3 was released from LPS-activated
microglia, and the galectin-3 could bind to PC12 cells only
when these cells were desialylated, and when bound could
opsonise these cells for phagocytosis by microglia. Galectin-
3 preferentially binds to N-acetyl-lactosamine residues on
glycoproteins and glycolipids, but this binding is normally
blocked by terminal sialic acid residues on mammalian cells
(32). On bacteria, galectin-3 normally binds the sugar residues of
LPS, although for some bacterial species the binding of galectin-
3 to LPS is not mediated by sugar residues (33). Galectin-
3 opsonized cells may stimulate microglial phagocytosis via
binding to microglial MerTK (9). However, we (34) recently
reported that galectin-3 can also bind the phagocytic receptor
TREM2, and thus galectin-3 could potentially opsonise via
TREM2 on microglia, but this requires further investigation.
Galectin-3 can also act as an alarmin via activating TLR4 on
microglia (8). Thus, like calreticulin, galectin-3 can have multiple
adaptive roles in orchestrating the response to LPS or gram-
negative bacteria.
What is the relevance of this work to the in vivo situation,
and what is the translational potential of this work for treatment
of disease? Calreticulin can be found in the serum of healthy
humans (at 5 ng/ml), and increases with inflammatory disease
(35). Thus, serum calreticulin has the potential to opsonise
bacteria in vivo, and the finding of calreticulin bound to LPS in
the sera of patients with chronic bacterial infections suggests that
is does (26).
Calreticulin is also found in human CSF (36), and thus has
the potential to opsonise bacteria in the brain. Macrophages have
been shown to release calreticulin that opsonizes mammalian
cells for phagocytosis by the macrophages (37), supporting
the possibility that this may occur also with bacteria as
targets. Phagocytosis of cancer cells induced by calreticulin
on their surface has been shown to result in presentation
of antigens from the cancer cell on the phagocyte together
with MHCII, resulting in an adaptive immune response to
the cancer (14, 15). Indeed, calreticulin has been used as
an adjuvant to induce an adaptive response to antigen (38).
Thus, phagocytosis of bacteria opsonized with calreticulin
might in principle result in presentation of antigens from
the bacteria by phagocytes to T cells, but this would have
to be tested. If this is correct, it may be worth testing
whether calreticulin injections during a bacterial infection help
clear the infection by (i) opsonizing the bacteria, and (ii)
enhancing phagocytosis and presentation of antigens from
the bacteria.
Galectin-3 is also found in human plasma and CSF, and
levels increases with disease (39, 40). Galectin-3 levels also
increase in mouse and humans during fungal infection and play
roles in reducing infection (41). The interaction of galectin-
3 with LPS from different species of bacteria enhances the
binding and interaction of LPS with neutrophils (33). Galectin-
3 has been shown to limit infections by the gram-negative
bacteria Helicobacter pylori (42), but also limits infection by
gram-positive Streptococcus pneumoniae partly by increasing
neutrophil phagocytosis of the bacteria (43). Thus, there is at least
indirect evidence that galectin-3 may limit bacterial infections
in vivo, potentially by acting as an opsonin, but this requires
further investigation. If so, it may be worth testing whether
galectin-3 injections during a bacterial infection help clear
the infection by opsonizing the bacteria. As with calreticulin,
there is also the possibility that injection of dead bacteria
opsonized with galectin-3might induce phagocytosis and antigen
presentation by antigen-presenting cells, promoting an adaptive
immune response.
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Figure S1 | Microglial calreticulin and galectin-3 are upregulated following LPS
stimulation. Calreticulin (A) and galectin-3 (B) mRNA were quantified in BV2
microglial cells treated with or without LPS (100 ng/ml) for 24 h, and expression
normalized to actin mRNA levels. Values are means ± SEM of at least three
independent experiments. Statistical comparisons were made via student’s t-test.
∗p < 0.05, ∗∗p < 0.01.
Figure S2 | BV2 microglia rapidly phagocytose pHrodo-conjugated E. coli
bacteria in vitro. Significant levels of phagocytosis were detected within 60min
(compared to the “0 min” control) with phagocytic saturation reached between
120 and 180min. Values are means ± SEM of at least three independent
experiments. Statistical comparisons were made via one-way ANOVA. ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
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